CLDX Celldex Therapeutics, Inc.
Price Chart
Executive Summary
Celldex presented positive Phase 1 data for CDX-622, a bispecific antibody targeting SCF and TSLP, at EAACI. The drug showed rapid, durable, dose-dependent reductions in serum tryptase (indicating mast cell depletion) and was well-tolerated at all doses with no dose-limiting toxicities or related serious adverse events. This validates a novel mechanism (neutralizing soluble SCF to selectively inhibit KIT signaling in mast cells) and supports advancing into Phase 1b proof-of-concept studies in asthma, allergic rhinitis, and food allergy.
Actionable Insight
The clean safety profile and novel mechanism validation are significant for Celldex's mast cell franchise. Watch for initiation of Phase 1b asthma data and subsequent proof-of-concept readouts in allergic rhinitis/food allergy, which could further de-risk the platform. The stock's 91% analyst bullish consensus and prior strong positive T+20 alpha on long calls suggest the market may reward this data.
Key Facts
- CDX-622 induced rapid, profound, dose-dependent, and durable reductions in serum tryptase, indicating tissue mast cell depletion.
- No dose-limiting toxicities or related serious adverse events; most common adverse event was Grade 1 headache.
- No changes in hair/skin pigmentation or meaningful impact on hematologic parameters, addressing a key safety concern for KIT-targeting therapies.
- CDX-622 exhibited monoclonal antibody-like pharmacokinetics with extended half-life and good subcutaneous bioavailability.
- Phase 1b proof-of-mechanism study in mild to moderate asthma is ongoing; additional proof-of-concept studies in allergic rhinitis and food allergy are planned.
- Celldex also presented non-human primate data showing targeting soluble SCF depletes mast cells without affecting spermatogenesis or melanogenesis.
- CDX-622 builds on Celldex's barzolvolimab platform, which is in Phase 3 for chronic urticaria and Phase 2 for prurigo nodularis and atopic dermatitis.
Financial Impact
No financial data provided; clinical-stage biotech with no approved products or revenue. Positive Phase 1 data de-risks the CDX-622 program and expands Celldex's pipeline optionality in inflammatory diseases.
Risk Factors
- CDX-622 is still in early-stage development (Phase 1b); clinical failure in later-stage trials remains a risk.
- Competition from other mast cell-targeting therapies (e.g., barzolvolimab, other anti-SCF/TSLP agents) could limit commercial potential.
- No financial data or guidance provided; the company's cash runway and ability to fund multiple Phase 2 programs is not disclosed.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311438 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 14, 2026
today
|
Press Release
| — | awaiting T+20 | — | — |
|
Jun 14, 2026
1d ago
|
Press Release
| — | awaiting T+20 | — | — |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $29.33 awaiting T+20 | awaiting T+20 | — | $31.27 (+6.61%) |
|
Jun 10, 2026
4d ago
|
Press Release
| $29.33 awaiting T+20 | awaiting T+20 | — | $31.27 (+6.61%) |
|
May 7, 2026
5w ago
|
8-K
| $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $31.27 (−7.95%) |
|
May 7, 2026
5w ago
|
Press Release
| $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $31.27 (−7.95%) |
|
Apr 6, 2026
9w ago
|
Press Release
| $31.37 $32.77 | ▲ +4.46% | ▼ −4.52% | $31.27 (−0.32%) |
|
Apr 2, 2026
10w ago
|
Press Release
| $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.27 (+0.68%) |
|
Apr 1, 2026
10w ago
|
424B5
| $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.27 (+0.68%) |
|
Apr 1, 2026
10w ago
|
Press Release
| $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.27 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access